Research shows that blocking a liver protein called MAGL can prevent bone loss caused by high-fat diet-induced liver damage in mice. According to Gram Research analysis of this 2026 study, mice treated with MJN110 (a MAGL inhibitor) showed significantly reduced liver scarring and prevented activation of bone-destroying cells, protecting their bones from damage. This discovery identifies a new potential treatment target for hepatic osteoporosis, though human studies are still needed.
According to Gram Research analysis, scientists discovered a new connection between fatty diets, liver damage, and weak bones. When people eat too much fat, it can damage the liver and trigger a chain reaction that weakens bones. Researchers found that blocking a specific protein called MAGL in liver cells can stop this damage. In studies with mice, blocking MAGL reduced liver scarring and prevented bone loss caused by high-fat diets. This discovery could lead to new treatments for people whose bones become weak because of liver disease, offering hope for a condition that’s hard to treat today.
Key Statistics
A 2026 research article published in the Journal of the Endocrine Society found that blocking the MAGL protein with the drug MJN110 significantly reduced liver fibrosis in mice fed high-fat diets.
According to the study, mice with high-fat diet-induced liver fibrosis showed elevated osteoclast activation (bone-destroying cells) in their bones, but this activation was substantially attenuated when treated with MJN110.
The research demonstrated that high-fat culture medium upregulated both MAGL and CB1R expression in mouse hepatocytes, establishing a direct link between dietary fat and liver protein changes that affect bone health.
The Quick Take
- What they studied: How blocking a liver protein called MAGL can prevent bone loss in mice fed high-fat diets that damage their livers
- Who participated: Male mice were fed either normal or high-fat diets to create liver damage. Researchers also studied liver cells in laboratory dishes to understand the exact mechanisms
- Key finding: Blocking MAGL with a drug called MJN110 reduced liver scarring and prevented the activation of bone-eating cells (osteoclasts), protecting bones from damage
- What it means for you: This research suggests a potential new treatment path for bone loss caused by liver disease, though human studies are still needed to confirm these findings work in people
The Research Details
This research combined laboratory experiments with animal studies. First, scientists grew liver cells in dishes and exposed them to high-fat conditions to see what happens. They discovered that fat triggers the liver to make more of a protein called MAGL. Then they used a drug called MJN110 to block MAGL and measured what changed in the cells.
Next, they tested this in living mice. Some mice ate normal food while others ate high-fat diets to damage their livers. The researchers gave some of the high-fat-diet mice the MJN110 drug and compared their bones and livers to untreated mice. They measured bone damage, liver scarring, and the activity of bone-destroying cells.
This multi-step approach allowed researchers to understand both how the process works at the cellular level and whether blocking MAGL actually helps in living animals.
This research approach is important because it connects two separate body systems—the liver and bones—that doctors usually treat separately. By studying both cells in dishes and whole animals, the researchers could prove that MAGL is the actual cause of bone loss, not just something that happens alongside it. This type of evidence is necessary before testing treatments in humans.
The study was published in the Journal of the Endocrine Society, a respected scientific journal. The researchers used multiple methods to confirm their findings, including gene silencing (turning off the MAGL gene) and drug treatment (using MJN110), which strengthens confidence in the results. However, this research was only done in mice, so results may not directly apply to humans. The sample size of mice was not specified in the abstract, which is a limitation.
What the Results Show
When liver cells were exposed to high-fat conditions in the laboratory, they produced significantly more MAGL protein. This increase in MAGL was connected to increased expression of another protein called CB1R and markers of cell death (SMAD3). When researchers blocked MAGL using the drug MJN110, CB1R expression decreased and signs of liver cell death reduced, suggesting less liver damage.
In the animal studies, mice fed high-fat diets developed liver fibrosis (scarring). When these mice received MJN110 injections, their liver scarring was significantly reduced compared to untreated mice. More importantly, the bones of treated mice showed much less damage from bone-eating cells (osteoclasts) compared to untreated mice with liver disease.
The researchers also confirmed these findings by genetically silencing the MAGL gene in liver cells. This produced the same protective effects as the drug, proving that MAGL itself is responsible for the bone damage, not something else triggered by the drug.
The study revealed that the liver communicates with bone cells through chemical signals. When MAGL is active in damaged livers, it triggers the release of substances that activate osteoclasts (bone-eating cells). By blocking MAGL, these harmful signals were reduced. The research also showed that CB1R, a protein involved in inflammation and cell death, is directly controlled by MAGL activity.
Previous research established that liver disease can cause bone loss through a connection called the liver-bone axis, but the exact mechanism was unknown. This study identifies MAGL as a key player in this process. The findings build on earlier work showing that high-fat diets damage the liver and that liver damage affects bone health, but this is the first research to pinpoint MAGL as a treatable target.
This research was conducted only in male mice, so results may differ in females or in humans. The study did not test the drug in human patients, so it’s unknown whether MJN110 would be safe or effective in people. The exact dose and duration of treatment needed in humans remains unknown. Additionally, the study focused on one specific protein (MAGL) and may not account for other factors involved in liver-related bone loss.
The Bottom Line
Based on this research, blocking MAGL appears promising for treating bone loss caused by liver disease (moderate confidence level, as human studies are needed). Current recommendations remain to maintain a healthy diet low in saturated fats, limit alcohol consumption, and maintain regular exercise to prevent both liver disease and bone loss. Anyone with liver disease should discuss bone health screening with their doctor.
This research is most relevant to people with liver disease or fatty liver disease who are experiencing bone loss. It may also interest people at high risk for liver disease due to obesity or poor diet. Healthcare providers treating liver disease should note this potential new treatment avenue. People without liver disease do not need to change their behavior based on this single study.
If this research leads to human trials, it would likely take 5-10 years before a new treatment becomes available. In the meantime, preventing liver disease through diet and lifestyle remains the most practical approach to protecting bone health.
Frequently Asked Questions
Can a fatty diet cause weak bones through liver damage?
Research shows that high-fat diets can damage the liver and trigger a chain reaction affecting bones. A 2026 study found that liver damage from fatty diets activates bone-destroying cells, leading to bone loss through a liver-bone communication pathway.
What is MAGL and why does it matter for bone health?
MAGL is a protein that increases in the liver when exposed to high-fat conditions. Blocking MAGL reduced both liver scarring and bone loss in mice, suggesting it’s a key target for treating bone loss caused by liver disease.
Is there a treatment available now for bone loss from liver disease?
This research identified MAGL as a potential treatment target, but the drug MJN110 has only been tested in mice. Human clinical trials would be needed before this becomes an available treatment. Current management focuses on preventing liver disease through diet and lifestyle.
How can I protect my bones if I have liver disease?
Maintain adequate calcium and vitamin D intake, engage in weight-bearing exercise regularly, avoid high-fat and high-alcohol diets, and work with your healthcare provider on liver-specific treatment. Bone density screening may be recommended to monitor bone health.
Does this research apply to women or just men?
This study was conducted only in male mice, so results may differ in females. More research is needed to determine whether MAGL inhibition would have similar protective effects on bones in women with liver disease.
Want to Apply This Research?
- Track daily fat intake (grams) and weekly bone-supporting activities like weight-bearing exercise. Set a goal to reduce saturated fat intake by 10-20% and increase weight-bearing exercise to 3+ days per week
- Users can log meals to monitor fat intake, set reminders for calcium and vitamin D intake (nutrients important for bone health), and track weight-bearing exercises like walking, jogging, or strength training
- Monthly review of fat intake trends and exercise consistency. Quarterly check-ins with healthcare provider for liver health markers and bone density screening if at risk for liver disease
This research was conducted in mice and has not been tested in humans. The findings suggest a potential new treatment approach but do not constitute medical advice. Anyone with liver disease or concerns about bone health should consult with a healthcare provider before making changes to diet or treatment. This article is for educational purposes and should not replace professional medical guidance. MJN110 is not currently approved for human use.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.